Collaborative Ocular Antiangiogenic Study of Ukraine. Multicentral, Open-label, Randomized, Prospective Study of Antiangiogenic Therapy of Choroidal Neovascularisation Associated With Central Chorioretinitis
Latest Information Update: 07 Feb 2023
At a glance
- Drugs Aflibercept (Primary) ; Ranibizumab (Primary)
- Indications Choroidal neovascularisation
- Focus Therapeutic Use
- Acronyms COAST_UAcCNV
- 02 Feb 2021 Planned End Date changed from 31 Dec 2020 to 31 Jan 2022.
- 02 Feb 2021 Planned primary completion date changed from 1 Jul 2020 to 31 Dec 2021.
- 04 Feb 2020 New trial record